Research Reports | Market Assessment
April 2015

Clostridium difficile Infections (Severe and Severe Recurrent)/Clostridium difficile-Associated Diarrhea | Decision Base | US | 2015

What Clinical Improvements Will Differentiate Emerging Therapies in a Market with High Unmet Need and Rising Use of Microbiome-Based Treatments?

Clostridium difficile infection (CDI) and Clostridium difficile-associated diarrhea (CDAD) are often the cause of nosocomial and antibiotic-associated diarrhea in hospitalized patients and other healthcare settings. Although standard-of-care antibiotics are relatively effective, the virulence of CDI is increasing, and standard antibiotic therapies are associated with high initial recurrence rates. Interviewed thought leaders report that severe and severe recurrent CDI/CDAD are areas of critical unmet need, and these physicians are hoping for superior clinical cure and recurrence rates from emerging CDI/CDAD therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports